Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial

        Klaus F Rabe, Bartolome R Celli, Michael E Wechsler, et al

        Lancet Respiratory Medicine 2021 July 21

        High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap

        Pei Yee Tiew, Albert Yick Hou Lim, Holly R Keir, et al

        Chest 2021 August 5

        慢阻肺患者中的曲霉致敏问题国内学者也有关注，早在2014年孙永昌教授团队就报告了慢阻肺中曲霉致敏和ABPA的发生情况及其对慢阻肺症状及肺功能的影响。

        近期我们的临床研究也证实有曲霉定植的慢阻肺患者急性加重风险上升。

        因此，慢阻肺患者下呼吸道曲霉定植/致敏/感染的出现、重叠和转换值得临床关注。

        Virus-induced Volatile Organic Compounds are Detectable in Exhaled Breath During Pulmonary Infection

        Faisal Kamal, Sacheen Kumar, Michael R Edwards, et al

        American Journal of Respiratory and Critical Care Medicine 2021 July 28

        Association Between Initiation of Pulmonary Rehabilitation and Rehospitalizations in Patients Hospitalized with COPD

        Mihaela S Stefan, Penelope S Pekow, Aruna Priya, et al

        American Journal of Respiratory and Critica lCare Medicine 2021 July 20

        从这项真实世界研究的大样本数据分析看，因慢阻肺急性加重住院的患者，在出院后90天内早期启动肺康复能够降低一年内重新住院的风险。之前RCT已经有类似结果，但是实际上接受了PR处方的患者比例很低，只有1.5%，因此需要确定有效的策略来增加PR的实施。

        Optimal Noninvasive Medicare Access Promotion: Patients with COPD Technical Expert Panel Report from the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society

        Nicholas S Hill, Gerard J Criner, Richard D Branson, et al

        Chest 2021 July 28